Vial - lyophilised powderSubcutaneous (SQ)5 mg
CJC 1295 DAC is researched for its effect on the body's own growth hormone release. The DAC component gives it a longer lasting profile than shorter acting alternatives. That distinction is the main reason it attracts interest in hormone research, rather than a promise of better sleep, muscle gain or recovery.
Shipping Information
Shipping Information
Free Shipping
Decor Outdoor offers free regular shipping on all orders shipped to residential or commercial addresses within the contiguous United States. Orders are delivered Monday through Friday (excluding holidays).Drop Shipping
We are an online-only luxury furniture and lighting boutique, and do not have a warehouse. Consequently, all orders are drop shipped directly from our manufacturers to your door. If your order includes items from more than one manufacturer, you will receive multiple deliveries. Because we are dependent on the on-hand inventory of our manufacturing partners, some items listed on our site may not actually be available right away. Please call us at 888.784.4644 or via our contact form with any stocking questions and we'll get in touch with the appropriate manufacturer for answers, before you place your order.Ground Shipping
Small parcel items ship regular ground via delivery services such as FedEx, UPS or DHL. Orders typically take 2-3 business days to process and in-stock items will usually be delivered 3-5 days from the date that they ship (depending on origin and destination). If there is a delay, you will be notified by email. No signature is required for standard ground shipping, so you may want to make arrangements to have packages brought inside soon after delivery, if you are unable to receive it in person.
Storage & Handling
Follow the storage instructions on your product label and the information supplied with your batch. Storage and handling requirements vary by product and presentation.
CJC 1295 DAC was designed to stay active longer than the natural signal that prompts growth hormone release. Understanding that longer exposure is central to understanding this peptide.
Growth hormone signalling and the effects of longer exposure. Clinical suitability is an individual medical question.
The PHI Perspective
Longer lasting does not automatically mean better. The timing and purpose of an intervention matter as much as the molecule itself.
For clinician-directed use only where permitted.
How It Works
It mimics a natural signal for growth hormone release. The DAC component helps it bind to a protein in the blood, extending how long it remains in circulation.
What the Research SuggestsHuman Phase I studies demonstrated prolonged pharmacokinetics and measurable increases in growth hormone and IGF-1. There are no established efficacy trials for performance, recovery or healthy ageing outcomes.
Evidence level: B. Phase I human pharmacokinetic and endocrine data; no efficacy trials
Storage & Handling
Store lyophilised vial at 2-8 C, protected from light.
Active compound: CJC-1295 with DAC (drug affinity complex)
Mechanism of ActionBinds the GHRH receptor on anterior pituitary somatotrophs, stimulating synthesis and release of growth hormone with consequent hepatic IGF-1 production. Albumin binding via the DAC moiety prevents renal clearance and enzymatic degradation, producing a continuous rather than pulsatile stimulus.
Clinical Evidence BasePhase I human studies demonstrated dose-dependent increases in growth hormone and IGF-1 sustained over several days, with acceptable short-term tolerability. No Phase II or III efficacy data for body composition, performance or longevity endpoints. Development was not continued.
Safety & PrecautionsReported effects include injection-site reactions, transient flushing, headache and fluid retention. Sustained non-pulsatile GH elevation raises theoretical concerns regarding insulin sensitivity, carpal tunnel symptoms and arthralgia, consistent with the known profile of growth hormone excess. Contraindicated where active malignancy is present or suspected, given IGF-1's mitogenic role. Baseline and periodic IGF-1 monitoring is advised in clinical use.
ContraindicationsActive or suspected malignancy; pregnancy and breastfeeding; proliferative diabetic retinopathy; acute critical illness; known hypersensitivity.
Literature & ReferencesTeichman SL et al. J Clin Endocrinol Metab, 2006 - prolonged stimulation of GH and IGF-1 by CJC-1295. | Jette L et al. Endocrinology, 2005 - human GRF analogue with albumin-binding DAC. | Ionescu M, Frohman LA. J Clin Endocrinol Metab, 2006 - pulsatile secretion under continuous GHRH stimulation.
